...
首页> 外文期刊>Respirology Case Reports >Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor
【24h】

Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor

机译:对表皮生长因子受体酪氨酸激酶抑制剂获得耐药后伴随的T790M突变和小细胞肺癌转化

获取原文

摘要

Abstract A 70-year-old man was admitted to our hospital with an abnormal chest X-ray shadow. Bronchoscopy revealed an adenocarcinoma tumour with an epidermal growth factor receptor (EGFR) exon 19 deletion. Positron emission tomography?¢????computed tomography scanning and magnetic resonance imaging showed advanced stage IV lung cancer. He was treated with erlotinib as a first-line drug, which maintained a clinical response for 16 months. After disease progression, a re-biopsy was done from the tumour in the right lower lobe. The obtained specimen harboured both small-cell lung cancer (SCLC) transformation with retention of the EGFR 19 deletion and the development of an EGFR T790M mutation. We came across a very rare condition of concomitant T790M mutation and SCLC transformation after acquired resistance to EGFR-tyrosine kinase inhibitor.
机译:摘要一名70岁男子因胸部X线影异常出现入院。支气管镜检查发现具有表皮生长因子受体(EGFR)外显子19缺失的腺癌肿瘤。正电子发射体层摄影术,计算机体层摄影术扫描和磁共振成像显示晚期IV期肺癌。他接受厄洛替尼作为一线药物治疗,该药物一直维持16个月的临床反应。疾病进展后,从右下叶的肿瘤进行再次活检。所获得的标本既保留了小细胞肺癌(SCLC)转化,又保留了EGFR 19缺失,又发展了EGFR T790M突变。在获得对EGFR-酪氨酸激酶抑制剂的抗性后,我们遇到了非常罕见的伴随T790M突变和SCLC转化的情况。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号